Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 07, 2019

SELL
$3.94 - $9.7 $1,201 - $2,958
-305 Closed
0 $0
Q3 2018

Oct 12, 2018

BUY
$8.6 - $11.26 $2,623 - $3,434
305 New
305 $3,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Dorsey Wright & Associates Portfolio

Follow Dorsey Wright & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Dorsey Wright & Associates with notifications on news.